SSC
KRTX

Syverson Strege & Co’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Syverson Strege & Co’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6
Closed -$1.09K – 656
2023
Q1 		$1.09K Buy
+6
New +$1.15K ﹤0.01% 598

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Syverson Strege & Co's KRTX Position: Q2 2023 in Review

Syverson Strege & Co sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 6 shares — an estimated $1.09K sold.

Syverson Strege & Co first reported a position in KRTX in Q1 2023 and held it in 1 quarter. The position peaked at $1.09K in Q1 2023. 289 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

  • Syverson Strege & Co reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 6 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.09K.
  • Syverson Strege & Co first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Syverson Strege & Co's Karuna Therapeutics, Inc. Common Stock position peaked at $1.09K in Q1 2023.
  • 289 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.